Gastric cancer is one of the most common and aggressive malignancies. Both bacterial virulence factors and host chronic inflammation are thought to promote gastric cancer development. In this study, we investigated the potential involvement of follicular helper T cells in gastric cancer. Functions of follicular helper T subsets were examined in Helicobacter pylori-infected gastric cancer patients and H. pylori-infected but asymptomatic individuals. We found that the follicular helper T cells in gastric cancer individuals were skewed toward the Th1 and Th17 subsets compared to those in H. pylori-infected but asymptomatic individuals. In a naive B cell-follicular helper T cell coculture, the Th1-follicular helper T cells by themselves were ineffective at stimulating a robust antibody response, unlike the Th2-follicular helper T and Th17-follicular helper T cells. However, Th1-follicular helper T cells significantly promoted the immunoglobulin G response in collaboration with other follicular helper T subsets, through the secretion of interferon gamma. We also found that Th1-follicular helper T cells suppressed the development of interleukin-10 + regulatory B cells, a cell type previously thought to protect H. pylori-infected individuals from tissue damage. In addition, the frequency of Th1follicular helper T cells in gastric cancer patients was negatively correlated with the disease-free survival of gastric cancer patients after tumor resection. These results suggested that dysregulation of follicular helper T subsets in gastric cancer patients, characterized by increased Th1-follicular helper T cells, contributed to inflammation and tumor development.
Introduction
Approximately 50% of the world population is infected with Helicobacter pylori in the gastrointestinal tract, but the clinical outcome of H. pylori infection is highly variable. The vast majority of infected individuals do not develop symptoms, but approximately 10%-15% individuals develop peptic ulcers and 1%-3% individuals develop gastric cancer; it is the fifth most common cancer and the third most common cause of cancer-related mortality worldwide. [1] [2] [3] It is now clear that the chronic inflammation induced by H. pylori is a major risk factor for gastric cancer development. Several bacterial factors, such as the bacterial proteins CagA and VacA, have been found to interfere with host immunity and induce tissue injury, leading to chronic inflammation. Infection with CagA + H. pylori strain confers a higher cancer risk than infection with other strains, which is correlated with increased likelihood of p53 mutations and elevated proinflammatory cytokine interleukin 8 (IL-8) secretion. 4, 5 VacA, on the contrary, blocks T cell proliferation by inducing cell cycle arrest and possibly interferes with the downstream signaling of T cell receptor (TCR) and IL-2 receptors. 6 However, infection by high-risk H. pylori strains does not always result in gastric cancer development. Many immunity-related factors are thought to play a role in cancer pathogenesis. Studies examining several human populations have found that genetic polymorphisms in IL-1β, tumor necrosis factor alpha (TNF-α), IL-10, and the promoter region of IL-8, are directly associated with the risk of developing gastric cancer. [7] [8] [9] In murine models, the development of gastric pathology after infections with H. felis is dependent on the presence of T cells. In mice lacking both T cells and B cells, H. felis infection results in no observable changes in gastric epithelial cells, while in mice lacking only B cells, severe atrophy and metaplasia are observed. 10, 11 These murine gastric tissue injuries appear to be primarily induced by Th1 responses. The susceptible C57BL/6 strain preferentially mounts a Th1-type response after challenge by Helicobacter, while the resistant BALB/c mice preferentially mount a Th2-type response. 12 Moreover, deletion of the Th1 signature cytokine interferon gamma (IFN-γ) could protect the Helicobacter-challenged mice from gastric injury, while deletion of the Th2 signature cytokine IL-4 exacerbates gastric injury. 13 Furthermore, infusion of IL-4 in mice before Helicobacter infection prevents IFN-γ-mediated pathology. 14 Together, these studies demonstrated that robust Th1-type responses represent a major risk in gastric cancer development in the host.
Recently, the participation of follicular helper T (Tfh) cells in cancer is being increasingly recognized. The germinal center (GC) Tfh cell is the key cell type in the formation and maintenance of the GC, which allows B cell proliferation, somatic hypermutation, and plasmablast/plasma cell generation. 15, 16 In the peripheral blood, the CD4 + CXCR5 + T cells, but not CD4 + CXCR5 − T cells, are capable of inducing naive B cell plasmablast differentiation and long-lasting humoral immunity and are considered GC Tfh-equivalent. [17] [18] [19] Studies have also found that peripheral Tfh cells were composed of Th1-like, Th2-like, and Th17like subsets, based on their mutually exclusive IFN-γ, IL-4, and IL-17 expression. 18 These results suggest a possibility that in addition to enhancing B cell responses, Tfh cells could also modulate immunity through cytokine production. Interestingly, favorable outcomes were found in breast cancers with high Tfh infiltration in the tumor. 20 Similarly, impaired Tfh cell function was associated with progression of hepatitis B virus (HBV)-related hepatocellular carcinoma. 21 These studies demonstrated that Tfh cells contributed to anti-tumor immunity. In gastric cancer development, the roles of Tfh cells and Tfh subsets are still unclear. Given that gastric cancer is associated with chronic Th1-type inflammation, the involvement of different Tfh subsets in reducing and/or increasing the risk of gastric cancer in H. pylori-infected individuals should be examined.
Materials and methods

Subjects
A total of 16 H. pylori-infected gastric cancer patients and 9 age-and gender-matched H. pylori-infected but asymptomatic healthy individuals participated in this study and provided fasting venous blood samples by venipuncture. All participants provided written informed consent, and the study procedures and use of human samples were approved by the ethics committee of the 155th Central Hospital of PLA. Patient information was analyzed by DICAT (Vancouver, Canada). At the time of sample collection, patients and controls were not taking medications and did not present signs of acute infections, chronic HBV, hepatitis C virus (HCV) or HIV infections, concurrent cardiovascular diseases, or autoimmune symptoms. Cancer stage was assessed using the tumor-node-metastasis (TNM) system described by the 7th Union for International Cancer Control. 22 A volume of 25-30 mL heparinized peripheral blood was layered on top of 10 mL Ficoll-Paque Plus (Amersham Biosciences, Little Chalfont, UK) and centrifuged for 30 min under 300g. The peripheral blood mononuclear cells (PBMCs) were then obtained by aspirating the murky layer.
Flow cytometry
Fluorescently labeled monoclonal anti-human antibodies, including CD3, CD4, CXCR5, CD45RA, CD45RO, IFN-γ, IL-4, IL-17, CXCR3, CCR6, and IL-10, as well as corresponding isotype controls, were purchased from BioLegend (San Diego, CA, USA). PBMCs were stimulated with 2 µg/mL of Staphylococcal enterotoxin B (SEB) for 24 h at 37°C in 5% CO 2 . GolgiStop and GolgiPlug (BD Pharmingen, Franklin Lakes, NJ, USA) were added to PBMCs 5 h before staining. The PBMCs were then washed in fluorescence-activated cell sorting (FACS) buffer (2% fetal bovine serum (FBS) in phosphate-buffered saline (PBS)) and treated with surface antibodies and Dead Cell Stain Aqua (Invitrogen, San Diego, CA, USA) for 30 min at 4°C. Excess surface antibodies were removed by two washings in FACS buffer, and the PBMCs were fixed and permeabilized in CytoFix/ CytoPerm (BD Pharmingen). Intracellular antibodies were dissolved in 1× Perm Wash (BD Pharmingen) and incubated with PBMCs for 30 min at 4°C. The cells were then washed twice in 1× Perm Wash and analyzed in BD FACSCanto cytometer (Franklin Lakes, NJ, USA).
For live sorting of Th1-Tfh, Th2-Tfh, Th17-Tfh, and CD19 + IgD + CD27 − naive B cells, PBMCs were surface stained with CD3, CD4, CXCR5, CXCR3, and CCR6 or with CD19, IgD, and CD27 for the fractionation of Tfh cells or the isolation of B cells, respectively. Excess antibodies were removed by washing twice in FAS buffer and sorted in BD FACSAria cell sorter (Franklin Lakes, NJ, USA).
Tfh-B cell coculture
Sorted Tfh cells and B cells were cocultured at 1 × 10 5 cells per mL each, in the presence of 2 µg/mL SEB, under 37°C and 5% CO 2 . Cell supernatant was harvested and replaced for every 3 days until day 12. In some experiments, Th1-Tfh cells were added at 1 × 10 5 to 5 × 10 5 cells per mL. A volume of 10 µg/mL IFN-γ-neutralizing antibody (NIB42) or corresponding isotype controls were added to the coculture as indicated.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) for human immunoglobulin (Ig)M, IgG, and IgA was performed using commercial kits from Abcam (Cambridge, UK). ELISA for human IFN-γ, IL-4, and IL-17A was performed using commercial kits from eBioscience (Waltham, MA, USA). Values below the respective detection limit in each kit were assigned a value of zero.
Statistical analyses
For comparisons between two groups, Mann-Whitney test was performed on samples from different individuals, while Wilcoxon matched-pairs test was performed on samples from the same individual but were treated under different experimental conditions. For comparisons between multiple groups, one-way or two-way analysis of variance (ANOVA) was performed. Pearson correlation test was used to examine correlations. Two-tailed p value less than 0.05 was used considered to be significant. All tests were computed by GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Results
Tfh cells in gastric cancer patients were skewed to the Th1/Th17 type
In peripheral blood, 8.7% ± 2.4% CD4 + T cells in stage I/II and 9.7% ± 2.6% CD4 + T cells in stage III/IV gastric cancer patients expressed CXCR5 (Figure 1(a) and (b)), which was on par with that in non-cancer controls (NCs). The vast majority of CD4 + CXCR5 + Tfh cells were CD45RO + (Figure 1(c) ), suggesting that they were memory T cells but not naive T cells.
To determine their subset differentiation, the expression of IFN-γ (Th1 marker), IL-4 (Th2 marker), and IL-17 (Th17 marker) was examined in SEB-treated T cells. The frequencies of IFN-γ and IL-17 expressing CD4 + CXCR5 + Tfh cells were significantly increased in gastric cancer patients than in NC (Figure 2(a) ). Consistent with previous findings, 18 The IFN-γ, IL-4, and IL-17 expressing CD4 + CXCR5 + Tfh cells were strongly concentrated in the CXCR3 + CCR6 − , the CXCR3 − CCR6 − , and the CXCR3 − CCR6 + subsets (Figure 2(b) ), respectively.
Th1-Tfh enhanced IgG antibody responses
The association between effector cytokine production and surface chemokine receptor expressions enabled us to fractionate total circulating Tfh cells into Th1-like, Th2-like, and Th17-like subsets. To examine the effects of Th1-Tfh and Th17-Tfh upregulation in gastric cancer patients, we examined their capacity in helping B cell antibody production. Naive CD19 + IgD + CD27 − B cells were cocultured with purified Th1-Tfh, Th2-Tfh, or Th17-Tfh cells in the presence of 2 µg/mL SEB for 12 days. The Ig content in the supernatant was examined for every 3 days by ELISA. A naive B cell-only culture was maintained as the negative control. We found that Th1-Tfh cells did not, by themselves, induce significant IgM, IgG, and IgA production from B cells, while both Th2-Tfh and Th17-Tfh induced significant amounts of IgM, IgG, and IgA (Figure 3(a) ). Interestingly, when Th1-Tfh was added to Th2-Tfh and Th17-Tfh coculture with B cells, we observed a significant upregulation of IgG production, which was associated with the amount of Th1-Tfh added (Figure 3(b) ). Given that the Th1-Tfh cells include IFN-γ-producing cells and that IFN-γ is a class switch factor for IgG, 23, 24 we suspected that the Th1-Tfh cells promoted IgG class switch through IFN-γ production. Indeed, neutralization of IFN-γ resulted in lowered IgG production ( Figure  3(c) ). Interestingly, the IgG isotype made up a larger percentage of total serum Ig in gastric cancer patients compared to healthy controls (Figure 3(d) ). Together, these results demonstrated that Th1-Tfh themselves did not induce Ig production of B cells but could assist the IgG secretion in collaboration with other Tfh subsets through IFN-γ production.
Th1-Tfh prevented regulatory B cell development
Recently, the crucial role of B cells in suppressing T cell inflammation has been increasingly recognized in autoimmune disorders, infectious diseases, and tumors. 25, 26 Several subsets of B cells, including CD24 hi CD38 hi B cells, B10 cells, and plasmablasts, have shown IL-10 secretion capacity and regulatory activity in numerous studies. These cells are collectively termed as regulatory B cells (Bregs). [27] [28] [29] [30] Interestingly, H. pylori-infected individuals who developed gastric tumor contained significantly lower frequencies of IL-10-secreting B cells than the H. pylori-infected individuals who did not develop gastric cancer. 31 Here, we investigated the effect of Tfh subsets on the development of Bregs. The frequency of IL-10-secreting B cells at the end of B cell-Tfh coculture was examined. Around 0.6%-7.4% of B cells expressed IL-10 by the end of B cell-all Tfh cell coculture (Figure 4(a) and (b) ). 30, 32 Depletion of Th1-Tfh in the coculture resulted in higher IL-10-expressing B cell frequency, while the depletion of Th2-Tfh or Th17-Tfh produced no significant effect (Figure 4(b) ). We then examined the frequency of IL-10-expressing B cells cultured alone or with fractionated Th1-Tfh, Th2-Tfh, or Th17-Tfh. Both Th2-Tfh and Th17-Tfh significantly increased the number of IL-10-expressing B cells, while the Th1-Tfh did not (Figure 4(c) ). Furthermore, the peripheral blood frequency of IL-10-expressing B cells in gastric cancer patients was inversely correlated with the peripheral blood frequency of total Tfh cells as well as Th1-Tfh cells (Figure 4(d) ). To assess whether B cells after coculture with Th1-Tfh cells also presented reduced regulatory capacity, we isolated CD19 + B cells from the coculture with Th1-Tfh, Th2-Tfh, and Th17-Tfh cells. These CD19 + B cells were then cocultured with anti-CD3/CD28-pulsed CD3 + T cells. Interestingly, the highest IFN-γ production was observed in CD3 + T cells cocultured with CD19 + B cells from the Th1-Tfh coculture (Figure 4(e) ). Together, these results suggested that the Th1-Tfh cells could suppress regulatory B cell development.
Low Th1-Tfh frequency was associated with better survival
The gastric cancer patients were followed-up for 2 years after receiving curative resection. The months of survival from the day of surgery to tumor recurrence or death were recorded. We found that low frequency of Th1-Tfh cells was associated with better survival. The frequency of total Tfh cells, Th2-Tfh cells, or Th17-Tfh cells was not correlated with patient survival time after surgery ( Figure 5 ). 
Discussion
In this study, we demonstrated a dysregulation of Tfh cells in gastric cancer patients, characterized by an overrepresentation of the IFN-γ-expressing Th1-Tfh subset and the IL-17expressing Th17-Tfh subset. Interestingly, the frequency of total Tfh cells and Th1-Tfh cells was negatively correlated with the disease-free survival time of gastric cancer patients after tumor resection. These results are consistent with earlier findings that IFN-γ-mediated immunity was a driving factor in gastric atrophy and suggested that dysregulated Tfh cells contributed to cancer development.
We also demonstrated the novel finding that although Th1-Tfh cells by themselves were ineffective at helping B cells to mount a robust IgG response, they could promote the IgG response in collaboration with other Tfh subsets through IFN-γ production in a cell number-dependent manner. Neutralization of IFN-γ reverted this effect. The (Figure 2(a) ) with the frequency of Tfh in CD4 + T cells (Figure 1(b) ) in the peripheral blood of gastric cancer patients. A line of best fit is shown. Pearson correlation test was performed. (e) Anti-CD3/CD28 (2 µg/mL each)-stimulated CD3 + T cells cocultured with CD19 + B cells harvested from the Th1-Tfh coculture presented higher IFN-γ secretion than CD3 + T cells with B cells from Th2-Tfh or Th17-Tfh cocultures. Friedman test was followed by Dunn's multiple-comparison test (**p < 0.01; ***p < 0.001).
role of humoral responses in the clinical outcome of H. pylori infection and gastric cancer is unclear. H. pyloritargeting IgA and IgG could be detected in the serum of H. pylori-infected individuals. 33, 34 It was shown that Africans, who had high H. pylori-infection rate but low gastric cancer rate, were polarized toward Th2-associated IgG1 responses but not toward Th1-associated IgG2 responses. 35 But evidence that directly associates cancer risk with modalities in humoral responses is lacking. Therefore, the in vivo effect of the Th1-Tfh cells on promoting IgG responses remains unclear.
Immunoregulatory functions mediated by IL-10secreting B cells are crucial in suppressing excessive inflammation in multiple autoimmune disorders. 36 In cancer, several studies suggested that regulatory functions mediated by B cells possibly contributed to disease progression. Significant infiltration of B cells was demonstrated in multiple human solid tumors. 37 In a murine breast cancer model, tumor-evoked regulatory B cells possibly promoted the conversion of resting CD4 + T cells to Foxp3 + regulatory T (Treg) cells, which promoted lung metastasis. 38 Regulatory B cells also accelerated the growth of hepatocellular carcinoma through the CD40/CD40L signaling. 39 In contrast, regulatory B cells appeared to protect H. pylori-infected individuals from the development of gastric cancer, since H. pylori-infected individuals with higher frequencies of CD24 + CD38 + regulatory B cells were less likely to develop gastric cancer than H. pylori-infected individuals with lower frequencies of CD24 + CD38 + regulatory B cells. 31 These CD24 + CD38 + regulatory B cells were shown to respond to H. pylori stimulation by secreting IL-10 and suppressing proinflammatory cytokine production by T cells in H. pylori-infected individuals, possibly protecting these individuals from inflammation-driven tissue damage. Here, we found that Th1-Tfh cells, but not Th2-Tfh or Th17-Tfh cells, suppressed the formation of IL-10-secreting B cells. Furthermore, the frequency of Th1-Tfh cells were negatively correlated with the frequency of IL-10 + B cells in peripheral blood. Together, these investigations demonstrated a novel finding that increased Th1-Tfh cells possibly exacerbated the tissue damage in H. pylori-infected individuals by suppressing the development of regulatory B cells. Another study in gastric cancer patients discovered that CD24 hi CD38 hi regulatory B cells suppressed IFN-γ and TNF-α from CD4 + T cells and converted CD4 + CD25 − effector T cells to CD4 + Foxp3 + Tregs, which, the authors suggested, might contribute to gastric cancer immune escape. 40 It is entirely possible that regulatory B cells exert different roles at different stages of H. pylori infection and gastric cancer. In HIV infection, upregulation of regulatory B cells and their secretion of IL-10 were shown to suppress the HIV-specific CD4 + and CD8 + T cell inflammation and were associated with viral load. 32, 41 Therefore, the Th1-Tfh-mediated suppression of IL-10 + B cells might have different effects on the clinical outcome at different time points. Initially, the Th1-Tfh-mediated suppression of IL-10 + B cells might increase the risk of tumor development, but once the cancer is developed, the suppression of IL-10 + B cells possibly enhances the overall anti-tumor immunity. In this study, we found that higher Th1-Tfh cell frequency was associated with shorter disease-free survival intervals following tumor resection, which was consistent with the idea that Th1-Tfh could increase the risk of tumor relapse. Further research is needed to elucidate the effects of Th1-Tfh cells on antitumor immunity after the tumor is developed.
